Skip to main content
. Author manuscript; available in PMC: 2015 Jan 28.
Published in final edited form as: Cancer Lett. 2012 Jan 27;342(2):10.1016/j.canlet.2012.01.020. doi: 10.1016/j.canlet.2012.01.020

Figure 2.

Figure 2

(A) Kaplan-Meier survival curves of biochemotherapy (BC) patients: Correlation of pre-BC serum RASSF1A methylation BM with overall survival (log-rank test, P = .013). Methylated: Patients with serum methylation of RASSF1A. Nonmethylated: Patients with no serum methylation of RASSF1A. (B) Correlation of pre-BC serum RARβ-2 methylation status with overall survival (log-rank test, P = .02). Methylated: Patients with serum methylation of RARβ-2. Nonmethylated: Patients with no serum methylation of RARβ-2. (C) Correlation of pre-BC serum methylation of at least one BM with overall survival (log-rank test, P = .01). ≥ 1 methylated: Patients with serum methylation of at least one BM. Nonmethylated: Patients with no serum methylation of genes. Figure reproduced with permission from Mori et al. 2005 [28].